GPC-HM111-100μg / 询价
GPC-HM111-500μg / 询价
GPC-HM111-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Human Glypican 1/GPC1 Protein
Recombinant Human Glypican 1/GPC1 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Asp24-Ser530 [Accession | P35052-1].
The protein has a predicted MW of 57.1 kDa. Due to glycosylation, the protein migrates to 70-135 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human Glypican 1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human Glypican 1 is greater than 95% as determined by SEC-HPLC.
Immobilized Human Glypican 1, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-Glypican 1 Antibody, hFc Tag with the EC50 of 21.9ng/ml determined by ELISA (QC Test).
Immobilized Human FGF basic at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Human Glypican 1, His Tag with the EC50 of 12.6ng/ml determined by ELISA.
CAR-T cells targeting glypican-1 (GPC1)-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models.
Glypican-1; FLJ38078; GPC1
(1) Kato D, Yaguchi T, Iwata T, Katoh Y, Morii K, Tsubota K, Takise Y, Tamiya M, Kamada H, Akiba H, Tsumoto K, Serada S, Naka T, Nishimura R, Nakagawa T, Kawakami Y. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. Elife. 2020 Mar 31;9:e49392. doi: 10.7554/eLife.49392. PMID: 32228854; PMCID: PMC7108862.
